OptiNose — Q4 2020 Earnings Presentation
21 slides from OptiNose's earnings presentation, Mar 3, 2021
Slide 1: Building a Leading ENT / Allergy Specialty Company Corporate Presentation
Building a Leading ENT / Allergy Specialty Company Corporate Presentat ion M a r c h 3 , 2 0 2 1 Exhibit 99.2
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this
Slide 3: Full Year 2020 Highlights
3 Full Year 2020 Highlights +31% XHANCE New Prescriptions Growth FY 2020/FY 2019 +59% XHANCE Net Revenue Growth FY 2020/FY 2019 $30.4 $48.4 2019 2020 ($M ) XHANCE Net Revenue $129M Full Year 2020 Operating Expenses (SG&A plus R&D) +70% XHANCE Prescriptions Growth FY 2020/FY 2019 +59%
Slide 4: Key Takeaways and Q4 2020 Highlights
4 Key Takeaways and Q4 2020 Highlights Largest Number of XHANCE New Prescriptions Since Launch Full Year 2020 Performance Aligned with Company Guidance Providing Initial Company Guidance for Q1 and Full Year 2021 Multiple factors support increased revenue growth in 2021 Topline data from one CS tria
Slide 5: XHANCE Launch Update
XHANCE Launch Update optinose_
Slide 6: New prescriptions of XHANCE increased 7% in Q4 2020 vs Q3 2020
6 New prescriptions of XHANCE increased 7% in Q4 2020 compared to Q3 2020 and increased 16% in Q4 2020 compared to Q4 2019 Estimated based on monthly prescription data from public source and XHANCE preferred pharmacy network. Q4 2020 XHANCE New Prescriptions 23.0 24.6 0 10 20 30 Q3 '20 Q4 '20 XHANCE
Slide 7: Prescriptions of XHANCE increased 36% in Q4 2020 compared to Q4 2019
7 Prescriptions of XHANCE increased 36% in Q4 2020 compared to Q4 2019 Estimated based on monthly prescription data from public source and XHANCE preferred pharmacy network. 21.2 22.3 18.7 23.0 24.6 33.0 33.7 43.8 46.1 49.3 0 20 40 60 80 Q4 '19 Q1 '20 Q2 '20 Q3 '20 Q4 '20 New Prescriptions Refills X
Slide 8: XHANCE Share of INS Prescriptions Within Target Physician Audience Increased
8 0.0% 1.0% 2.0% 3.0% 4.0% 5.0% 6.0% Q4 ‘20Q4 ‘19 Q3 ‘20Q1 ‘20 Q2 ‘20 XHANCE Share of INS Prescriptions Within the Target Physician Audience Increased in Q4 2020 and a Large Opportunity Remains New for 2021 - we increased the size of our target physician audience from ~10,000 to ~18,000 to include a
Slide 9: Number of XHANCE Prescribers by Prescribing Frequency
9 Physicians who had more than 15 XHANCE prescriptions filled by their patients in a quarter increased by 54% from Q4 2019 to Q4 2020 (1,275 versus 828) Estimated based on monthly prescription data from third parties and XHANCE preferred pharmacy network. 3,432 3,944 3,631 3,677 3,729 1,599 1,506 1,
Slide 10: Q4 2020 Financial Update
Q4 2020 Financial Update optinose_
Slide 11: Financial Review – Fourth Quarter 2020
11 Financial Review – Fourth Quarter 2020 Q4 2020 XHANCE Net Revenue Increased 41% Compared to Q4 2020 XHANCE Average Net Revenue per TRx $211 in Q4 2020 – $204 in Q4 2019 $185 for full year 2020 ‒ $198 for full year 2019 $11.1 $15.6 Q4 '19 Q4 '20 ($M ) XHANCE Net Revenue +41%
Slide 12: FY 2020 Operating Expenses
12 FY 2020 Operating Expenses $104.2 $105.4 $20.8 $23.4 2019 2020 SG&A and R&D Expenses (GAAP) SG&A R&D ($M) FY 2020 R&D increased 12% compared to FY 2019 Driven by the conduct of our CS clinical trials FY 2020 SG&A increased 1% compared to FY 2019 Increased volume related expenses offset by
Slide 13: First Quarter and Full Year 2021 Financial Guidance
13 First Quarter and Full Year 2021 Financial Guidance XHANCE Net Revenue ‒ FY 2021 expected to be at least $80 million ‒ 1Q 2021 expected to decrease compared to Q4 2020 similar to the pattern of calendar effect on XHANCE net revenue reported last year • Q1 2021 XHANCE net revenue per prescriptio
Slide 14: Chronic Sinusitis Trials
Chronic Sinusitis Trials optinose_
Slide 15: Chronic Sinusitis is a Large Market for XHANCE
15 Chronic Sinusitis (CS) is a Large Market for XHANCE that Includes Opportunities for Potential Partners Source: Palmer J et al . A cross-sectional population-based survey of the prevalence, disease burden, and characteristics of the US adult population with symptoms of chronic rhinosinusitis (CRS)
Slide 16: XHANCE Chronic Sinusitis Indication (sNDA)
16 XHANCE Chronic Sinusitis Indication (sNDA) The Chronic Sinusitis clinical research program includes two Phase 3b clinical trials Both trials are 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter studies Both trials have co-primary endpoints: 1) a measure of p
Slide 17: OPN-019 Pilot Study
17 OPN-019 Pilot Study Human in vivo data will supplement in vitro data Prior in vitro testing against SARS-CoV-2 with a candidate formulation produced a 4-log reduction in virus count Randomized, adaptive proof of concept single-dose study to evaluate change in viral load after OPN-019 in adu
Slide 18: Closing Remarks
Closing Remarks optinose_
Slide 19: Key Takeaways and Q4 2020 Highlights
19 Key Takeaways and Q4 2020 Highlights Largest Number of XHANCE New Prescriptions Since Launch Full Year 2020 Performance Aligned with Company Guidance Providing Initial Company Guidance for Q1 and Full Year 2021 Multiple factors support increased revenue growth in 2021 Topline data from one CS tri
Slide 20: Investor Relations – Optinose Investor Contact
20 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Operations 267-521-0531 1 - Optinose is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding the Company’s performance made by these an
Slide 21: Building a Leading ENT / Allergy Specialty Company Corporate Presentation
Building a Leading ENT / Allergy Specialty Company Corporate Presentat ion M a r c h 3 , 2 0 2 1